

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-39685

INMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

British Columbia, Canada

(State or other jurisdiction of  
incorporation or organization)

98-1067994

(I.R.S. Employer  
Identification No.)

Suite 310 - 815 W. Hastings Street,  
Vancouver, B.C.  
Canada

(Address of Principal Executive Offices)

V6C 1B4

(Zip Code)

(604) 669-7207

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class         | Trading Symbol(s) | Name of each exchange on which registered |
|-----------------------------|-------------------|---|
| Common Shares, no par value | INM               | The Nasdaq Stock Market LLC               |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

|                         |                                     |                           |                                     |
|-------------------------|-------------------------------------|---------------------------|-------------------------------------|
| Large accelerated filer | <input type="checkbox"/>            | Accelerated filer         | <input type="checkbox"/>            |
| Non-accelerated filer   | <input checked="" type="checkbox"/> | Smaller reporting company | <input checked="" type="checkbox"/> |
| Emerging growth company | <input checked="" type="checkbox"/> |                           |                                     |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes  No

As of May 13, 2022, the registrant had 14,641,645 common shares, without par value, outstanding.

## INDEX

|  | <b>Page</b>  |    |
|--|--|----|
| <b><u>PART I – FINANCIAL INFORMATION</u></b> |  |    |
| <u>ITEM 1.</u>                               | <u>CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</u>                                   | 1  |
| <u>ITEM 2.</u>                               | <u>MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u> | 27 |
| <u>ITEM 3.</u>                               | <u>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u>                            | 41 |
| <u>ITEM 4.</u>                               | <u>CONTROLS AND PROCEDURES</u>   | 41 |
| <b><u>PART II – OTHER INFORMATION</u></b>    |  |    |
| <u>ITEM 1.</u>                               | <u>LEGAL PROCEEDINGS</u>   | 42 |
| <u>ITEM 1A.</u>                              | <u>RISK FACTORS</u>  | 42 |
| <u>ITEM 2.</u>                               | <u>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</u>                           | 42 |
| <u>ITEM 3.</u>                               | <u>DEFAULTS UPON SENIOR SECURITIES</u>   | 42 |
| <u>ITEM 4.</u>                               | <u>MINE SAFETY DISCLOSURE</u>  | 42 |
| <u>ITEM 5.</u>                               | <u>OTHER INFORMATION</u>   | 42 |
| <u>ITEM 6.</u>                               | <u>EXHIBITS</u>  | 43 |
| <u>SIGNATURES</u>                            |  | 44 |

**PART I**

**ITEM 1. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS.**



**Unaudited Condensed Consolidated Interim Financial Statements of**

**InMed Pharmaceuticals Inc.**

**For the Three and Nine Months Ended March 31, 2022 and 2021**

Suite 310 – 815 West Hastings Street  
Vancouver, BC, Canada, V6C 1B4  
Tel: +1-604-669-7207



**InMed Pharmaceuticals Inc.**  
(Expressed in U.S. Dollars)  
March 31, 2022

| <b>INDEX</b>   | <b>Page</b> |
|--|-------------|
| <hr/>  |             |
| Financial Statements (Unaudited)   |             |
| • <a href="#">Condensed Consolidated Interim Balance Sheets</a>                                  | 3           |
| • <a href="#">Condensed Consolidated Interim Statements of Operations and Comprehensive Loss</a> | 4           |
| • <a href="#">Condensed Consolidated Interim Statements of Shareholders' Equity</a>              | 5           |
| • <a href="#">Condensed Consolidated Interim Statements of Cash Flows</a>                        | 6           |
| • <a href="#">Notes to the Condensed Consolidated Interim Financial Statements</a>               | 7-26        |

The accompanying notes form an integral part of these condensed consolidated interim financial statements.

**InMed Pharmaceuticals Inc.**

## CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (unaudited)

As at March 31, 2022 and June 30, 2021

Expressed in U.S. Dollars

|   | Note  | March 31,<br>2022<br>\$ | June 30,<br>2021<br>\$ |
|---|-------|-------------------------|------------------------|
| <b>ASSETS</b>   |       |                         |                        |
| <b>Current</b>  |       |                         |                        |
| Cash and cash equivalents                                     |       | 5,898,313               | 7,363,126              |
| Short-term investments  |       | 46,098                  | 46,462                 |
| Accounts receivable   |       | 70,554                  | 11,919                 |
| Inventories   | 4     | 1,420,382               | -                      |
| Prepays and other assets                                      |       | 1,311,539               | 956,762                |
| <b>Total current assets</b>                                   |       | <b>8,746,886</b>        | <b>8,378,269</b>       |
| <b>Non-Current</b>  |       |                         |                        |
| Property and equipment, net                                   | 5     | 1,002,846               | 326,595                |
| Intangible assets, net  | 6     | 2,355,401               | 1,061,697              |
| In-process research and development                           | 6     | 1,249,000               | -                      |
| Goodwill  | 6     | 2,023,039               | -                      |
| Other assets  |       | 108,625                 | 14,655                 |
| <b>Total Assets</b>   |       | <b>15,485,797</b>       | <b>9,781,216</b>       |
| <b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>                   |       |                         |                        |
| <b>Current</b>  |       |                         |                        |
| Accounts payable and accrued liabilities                      | 8     | 2,866,927               | 2,134,878              |
| Short-term debt   |       | 29,312                  | -                      |
| Current portion of lease obligations                          | 11    | 399,904                 | 80,483                 |
| Deferred revenue  |       | 8,902                   | -                      |
| Acquisition consideration payable                             | 7     | 800,457                 | -                      |
| <b>Total current liabilities</b>                              |       | <b>4,105,502</b>        | <b>2,215,361</b>       |
| <b>Non-current</b>  |       |                         |                        |
| Lease obligations   | 11    | 493,562                 | 189,288                |
| <b>Total Liabilities</b>                                      |       | <b>4,599,064</b>        | <b>2,404,649</b>       |
| <b>Shareholders' Equity</b>                                   |       |                         |                        |
| Common shares, no par value, unlimited authorized shares:     |       |                         |                        |
| 14,283,848 (June 30, 2021 - 8,050,707) issued and outstanding | 9     | 69,825,331              | 60,587,417             |
| Additional paid-in capital                                    | 9, 10 | 26,515,397              | 21,513,051             |
| Accumulated deficit   |       | (85,582,564)            | (74,852,470)           |
| Accumulated other comprehensive income                        |       | 128,569                 | 128,569                |
| <b>Total Shareholders' Equity</b>                             |       | <b>10,886,733</b>       | <b>7,376,567</b>       |
| <b>Total Liabilities and Shareholders' Equity</b>             |       | <b>15,485,797</b>       | <b>9,781,216</b>       |
| Commitments and Contingencies (Note 15)                       |       |                         |                        |
| Related Party Transactions (Note 17)                          |       |                         |                        |
| Subsequent Events (Note 18)                                   |       |                         |                        |

The accompanying notes form an integral part of these condensed consolidated interim financial statements.

**InMed Pharmaceuticals Inc.****CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)**

For the three and nine months ended March 31, 2022 and 2021

Expressed in U.S. Dollars

|   | Note | Three Months Ended<br>March 31 |                    | Nine Months Ended<br>March 31 |                    |
|---|------|--------------------------------|--------------------|-------------------------------|--------------------|
|   |      | 2022                           | 2021               | 2022                          | 2021               |
|   |      | \$                             | \$                 | \$                            | \$                 |
| Sales   |      | 309,585                        | -                  | 574,677                       | -                  |
| Cost of sales                                     |      | 127,308                        | -                  | 280,845                       | -                  |
| <b>Gross profit</b>                               |      | <b>182,277</b>                 | <b>-</b>           | <b>293,832</b>                | <b>-</b>           |
| <b>Operating Expenses</b>                         |      |                                |                    |                               |                    |
| Research and development and patents              |      | 1,753,545                      | 1,772,593          | 5,781,867                     | 3,621,697          |
| General and administrative                        |      | 1,915,017                      | 1,333,725          | 5,124,670                     | 2,918,067          |
| Amortization and depreciation                     | 5, 6 | 53,340                         | 27,421             | 131,669                       | 92,218             |
| <b>Total operating expenses</b>                   |      | <b>3,721,902</b>               | <b>3,133,739</b>   | <b>11,038,206</b>             | <b>6,631,982</b>   |
| <b>Other Income (Expense)</b>                     |      |                                |                    |                               |                    |
| Interest and other income                         |      | 30,964                         | 3,797              | 62,389                        | 11,192             |
| Finance expense                                   |      | -                              | -                  | -                             | (360,350)          |
| Unrealized gain on derivative warrants liability  |      | -                              | -                  | -                             | 242,628            |
| Foreign exchange gain (loss)                      |      | 32,996                         | 28,467             | (48,109)                      | (205,824)          |
| <b>Net loss for the period</b>                    |      | <b>(3,475,665)</b>             | <b>(3,101,475)</b> | <b>(10,730,094)</b>           | <b>(6,944,336)</b> |
| <b>Other Comprehensive Loss</b>                   |      |                                |                    |                               |                    |
| Foreign currency translation gain                 |      | -                              | -                  | -                             | 430,443            |
| <b>Total comprehensive loss for the period</b>    |      | <b>(3,475,665)</b>             | <b>(3,101,475)</b> | <b>(10,730,094)</b>           | <b>(6,513,893)</b> |
| <b>Net loss per share for the period</b>          |      |                                |                    |                               |                    |
| <b>Basic and diluted</b>                          | 12   | <b>(0.25)</b>                  | <b>(0.41)</b>      | <b>(0.81)</b>                 | <b>(1.11)</b>      |
| <b>Weighted average outstanding common shares</b> |      |                                |                    |                               |                    |
| <b>Basic and diluted</b>                          | 12   | <b>14,151,544</b>              | <b>7,549,040</b>   | <b>13,326,754</b>             | <b>6,277,824</b>   |

The accompanying notes form an integral part of these condensed consolidated interim financial statements.

**InMed Pharmaceuticals Inc.**
**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF SHAREHOLDERS' EQUITY (unaudited)**

For the three and nine months ended March 31, 2022 and 2021

Expressed in U.S. Dollars

|   | Note | Common Shares     |                   | Additional         | Accumulated         | Accumulated Other                                    | Total             |
|---|------|-------------------|-------------------|--------------------|---------------------|--|-------------------|
|   |      | #                 | \$                | Paid-in<br>Capital | Deficit             | Comprehensive<br>(Loss) Income -<br>Foreign Exchange |                   |
|   |      |                   |                   | \$                 | \$                  | \$   | \$                |
| <b>Balance June 30, 2020</b>                            |      | <u>5,220,707</u>  | <u>53,065,240</u> | <u>17,764,333</u>  | <u>(64,649,381)</u> | <u>(301,874)</u>                                     | <u>5,878,318</u>  |
| <b>Activity for the six months to December 31, 2020</b> |      |                   |                   |                    |                     |  |                   |
| Public offering   | 9    | 1,780,000         | 6,052,000         | -                  | -                   | -  | 6,052,000         |
| Share issuance costs                                    | 9    | -                 | (1,109,128)       | -                  | -                   | -  | (1,109,128)       |
| Loss and comprehensive income for the period            |      | -                 | -                 | -                  | (3,842,861)         | 430,443  | (3,412,418)       |
| Share-based compensation                                | 10   | -                 | -                 | 182,041            | -                   | -  | 182,041           |
| <b>Balance December 31, 2020</b>                        |      | <u>7,000,707</u>  | <u>58,008,112</u> | <u>17,946,374</u>  | <u>(68,492,242)</u> | <u>128,569</u>                                       | <u>7,590,813</u>  |
| <b>Activity for the three months to March 31, 2021</b>  |      |                   |                   |                    |                     |  |                   |
| Private placement                                       | 9    | 1,050,000         | 2,917,157         | 1,545,343          | -                   | -  | 4,462,500         |
| Reclassification of warrants                            | 9    | -                 | -                 | 1,763,980          | -                   | -  | 1,763,980         |
| Share issuance costs                                    |      | -                 | (337,852)         | (170,798)          | -                   | -  | (508,650)         |
| Loss for the period                                     |      | -                 | -                 | -                  | (3,101,475)         | -  | (3,101,475)       |
| Share-based compensation                                | 10   | -                 | -                 | 207,302            | -                   | -  | 207,302           |
| <b>Activity for the nine months to March 31, 2021</b>   |      | <u>2,830,000</u>  | <u>7,522,177</u>  | <u>3,527,868</u>   | <u>(6,944,336)</u>  | <u>430,443</u>                                       | <u>4,536,152</u>  |
| <b>Balance March 31, 2021</b>                           |      | <u>8,050,707</u>  | <u>60,587,417</u> | <u>21,292,201</u>  | <u>(71,593,717)</u> | <u>128,569</u>                                       | <u>10,414,470</u> |
|   |      |                   |                   |                    |                     |  |                   |
|   | Note | Common Shares     |                   | Additional         | Accumulated         | Accumulated Other                                    | Total             |
|   |      | #                 | \$                | Paid-in<br>Capital | Deficit             | Comprehensive<br>Income -<br>Foreign Exchange        |                   |
|   |      |                   |                   | \$                 | \$                  | \$   | \$                |
| <b>Balance June 30, 2021</b>                            |      | <u>8,050,707</u>  | <u>60,587,417</u> | <u>21,513,051</u>  | <u>(74,852,470)</u> | <u>128,569</u>                                       | <u>7,376,567</u>  |
| <b>Activity for the six months to December 31, 2021</b> |      |                   |                   |                    |                     |  |                   |
| Private placement                                       | 9    | 890,000           | 1,459,051         | 10,540,635         | -                   | -  | 11,999,686        |
| Share issuance costs                                    | 9    | -                 | (247,336)         | (1,786,831)        | -                   | -  | (2,034,167)       |
| Agents' warrants  |      | -                 | -                 | 739,920            | -                   | -  | 739,920           |
| Exercise of pre-funded warrants                         | 9    | 3,146,327         | 4,283,969         | (4,283,654)        | -                   | -  | 315               |
| Acquisition of BayMedica                                | 7    | 2,050,000         | 3,013,500         | -                  | -                   | -  | 3,013,500         |
| Loss for the period                                     |      | -                 | -                 | -                  | (7,254,429)         | -  | (7,254,429)       |
| Share-based compensation                                | 10   | -                 | -                 | 325,921            | -                   | -  | 325,921           |
| <b>Balance December 31, 2021</b>                        |      | <u>14,137,034</u> | <u>69,096,601</u> | <u>27,049,042</u>  | <u>(82,106,899)</u> | <u>128,569</u>                                       | <u>14,167,313</u> |
| <b>Activity for the three months to March 31, 2022</b>  |      |                   |                   |                    |                     |  |                   |
| Exercise of warrants                                    | 9    | 146,814           | 728,730           | (728,730)          | -                   | -  | -                 |
| Loss for the period                                     |      | -                 | -                 | -                  | (3,475,665)         | -  | (3,475,665)       |
| Share-based compensation                                | 10   | -                 | -                 | 195,085            | -                   | -  | 195,085           |
| <b>Activity for the nine months to March 31, 2022</b>   |      | <u>6,233,141</u>  | <u>9,237,914</u>  | <u>5,002,346</u>   | <u>(10,730,094)</u> | <u>-</u>   | <u>3,510,166</u>  |
| <b>Balance March 31, 2022</b>                           |      | <u>14,283,848</u> | <u>69,825,331</u> | <u>26,515,397</u>  | <u>(85,582,564)</u> | <u>128,569</u>                                       | <u>10,886,733</u> |

The accompanying notes form an integral part of these condensed consolidated interim financial statements.

**InMed Pharmaceuticals Inc.****CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited)**

For the nine months ended March 31, 2022 and 2021

Expressed in U.S. Dollars

|   | Note | 2022<br>\$          | 2021<br>\$         |
|---|------|---------------------|--------------------|
| <b>Cash provided by (used in):</b>                              |      |                     |                    |
| <b>Operating Activities</b>                                     |      |                     |                    |
| Net loss for the period   |      | (10,730,094)        | (6,944,336)        |
| Items not requiring cash:                                       |      |                     |                    |
| Amortization and depreciation                                   | 5, 6 | 131,669             | 92,218             |
| Share-based compensation  | 10   | 521,006             | 389,343            |
| Amortization of right-of-use assets                             |      | 226,061             | 88,620             |
| Loss on disposal of assets                                      |      | 11,355              | -                  |
| Interest income received on short-term investments              |      | 46                  | 159                |
| Unrealized gain on derivative warrants liability                |      | -                   | (242,628)          |
| Unrealized foreign exchange loss                                |      | 312                 | (571)              |
| Payments on lease obligations                                   |      | (232,633)           | (66,537)           |
| Finance expense   |      | -                   | 360,350            |
| Changes in non-cash working capital:                            |      |                     |                    |
| Inventories   |      | (933,260)           | -                  |
| Prepays and other assets  |      | (323,653)           | (1,192,936)        |
| Other non-current assets  |      | 6,580               | (14,161)           |
| Accounts receivable   |      | (22,535)            | (18,183)           |
| Accounts payable and accrued liabilities                        |      | (195,125)           | (235,892)          |
| Deferred revenue  |      | 3,760               | -                  |
| <b>Total cash used in operating activities</b>                  |      | <b>(11,536,511)</b> | <b>(7,784,554)</b> |
| <b>Investing Activities</b>                                     |      |                     |                    |
| Cash acquired from acquisition of BayMedica                     | 7    | 91,566              | -                  |
| Purchase of property and equipment                              |      | (39,108)            | -                  |
| <b>Total cash provided by investing activities</b>              |      | <b>52,458</b>       | <b>-</b>           |
| <b>Financing Activities</b>                                     |      |                     |                    |
| Shares issued for cash  | 9    | 12,000,001          | 12,472,500         |
| Share issuance costs  | 9    | (1,294,247)         | (1,534,602)        |
| Repayment of debt   |      | (261,514)           | -                  |
| Settlement of debt upon acquisition of subsidiary               |      | (425,000)           | -                  |
| <b>Total cash provided by financing activities</b>              |      | <b>10,019,240</b>   | <b>10,937,898</b>  |
| <b>Effects of foreign exchange on cash and cash equivalents</b> |      | <b>-</b>            | <b>494,960</b>     |
| <b>Increase (decrease) in cash during the period</b>            |      | <b>(1,464,813)</b>  | <b>3,648,304</b>   |
| <b>Cash and cash equivalents beginning of the period</b>        |      | <b>7,363,126</b>    | <b>5,805,809</b>   |
| <b>Cash and cash equivalents end of the period</b>              |      | <b>5,898,313</b>    | <b>9,454,113</b>   |

See Note 14 for Non-Cash Transactions

The accompanying notes form an integral part of these condensed consolidated interim financial statements.



**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**1. CORPORATE INFORMATION AND CONTINUING OPERATIONS**

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the *Business Corporations Act* of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry.

The Company’s shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “INM”. InMed’s corporate office and principal place of business is located at #310 – 815 West Hastings Street, Vancouver, B.C., Canada, V6C 1B4.

In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated interim financial statements are issued.

Through March 31, 2022, the Company has funded its operations primarily with proceeds from the sale of common stock. The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of \$10.7 million and \$6.9 million for the nine months ended March 31, 2022 and 2021, respectively. In addition, the Company had an accumulated deficit of \$85.6 million as of March 31, 2022 (June 30, 2021 - \$74.9 million). The Company expects to continue to generate operating losses for the foreseeable future.

As of the issuance date of these condensed consolidated interim financial statements, the Company expects its cash and cash equivalents of \$5.9 million as of March 31, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of fiscal 2023 (being the fourth calendar quarter of 2022). The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. As a result, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated interim financial statements are issued.

The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing stockholders.

These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will be able to meet its commitments, realize its assets and discharge its liabilities in the normal course. These condensed consolidated interim financial statements do not reflect adjustments to the carrying values of assets and liabilities that would be necessary if the Company was unable to continue as a going concern and such adjustments could be material.

**INMED PHARMACEUTICALS INC.**

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

**FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021**

(Expressed in U.S. Dollars)

---

**2. SIGNIFICANT AND NEW ACCOUNTING POLICIES**

(a) Basis of Presentation

These unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United States (“US GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended June 30, 2021.

These unaudited condensed consolidated interim financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and nine months ended March 31, 2022 and 2021 are not necessarily indicative of results that can be expected for a full year. These unaudited condensed consolidated interim financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended June 30, 2021, except for the new accounting guidance adopted during the period.

The functional currency of the Company and its subsidiaries is the U.S. Dollar. These condensed consolidated interim financial statements are presented in U.S. Dollars. References to “\$” and “US\$” are to United States (“U.S.”) dollars and references to “C\$” are to Canadian dollars.

(b) Use of Estimates

The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these condensed consolidated interim financial statements are the estimated fair values of the assets acquired and liabilities assumed in acquisitions, the estimate of useful life of intangible assets, the application of the going concern assumption, the impairment assessment for long-lived assets, and determining the fair value of share-based payments and warrants.

**INMED PHARMACEUTICALS INC.**

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

**FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021**

(Expressed in U.S. Dollars)

---

**2. SIGNIFICANT AND NEW ACCOUNTING POLICIES (cont'd)**

(c) COVID-19 Impacts

On March 11, 2020 the COVID-19 outbreak was declared a pandemic by the World Health Organization. The full extent to which the COVID-19 pandemic may directly or indirectly impact the Company's business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these condensed consolidated interim financial statements. While there was no material impact to the Company's condensed consolidated interim financial statements as of and for the three and nine months ended March 31, 2022, the Company's future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to the Company's consolidated financial statements in future reporting periods.

(d) Business Combinations

Business combinations are accounted for using the acquisition method. The fair value of total purchase consideration is allocated to the fair values of identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount being classified as goodwill. All assets, liabilities and contingent liabilities acquired or assumed in a business combination are recorded at their fair values at the date of acquisition. If the Company's interest in the fair value of the acquiree's net identifiable assets exceeds the cost of the acquisition, the excess is recognized in earnings or loss immediately. Transaction costs that are incurred in connection with a business combination, other than costs associated with the issuance of debt or equity securities, are expensed as incurred.

(e) Accounts Receivable

Accounts receivable are recorded at invoiced amounts, net of any allowance for doubtful accounts. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in existing accounts receivable.

The Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. Expected credit losses on our accounts receivable were immaterial as at March 31, 2022 and June 30, 2021.

(f) Inventories

Inventories are initially valued at weighted average cost and subsequently valued at the lower of weighted average cost and net realizable value. Costs included in inventories are raw materials, work-in-progress, and finished goods.

In determining any valuation allowances, the Company reviews inventory for obsolete, redundant, and slow-moving goods. At March 31, 2022, no amounts had been charged to the valuation allowance.

**INMED PHARMACEUTICALS INC.**

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

**FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021**

(Expressed in U.S. Dollars)

---

**2. SIGNIFICANT AND NEW ACCOUNTING POLICIES (cont'd)**

(g) Revenue Recognition

The Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services. ASC 606, *Revenue from Contracts with Customers* defines a five-step process to recognize revenue that requires judgment and estimates, including identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract, and recognizing revenue when or as the performance obligation is satisfied.

Revenue consists of manufacturing and distribution sales of bulk rare cannabinoids, which are generally recognized at a point in time when control over the products have been transferred to the customer. Control of the products are considered transferred to the customer once they have been shipped to the customer and title and risk of loss have been transferred to the customer and the Company has a present right to payment. Sales and other taxes that are required to be remitted to regulatory authorities are recorded as liabilities and excluded from sales. Limited rights of return, for claims of damaged or non-compliant products, exist with the Company's customers.

The Company has elected the practical expedient that allows it to recognize the incremental costs of obtaining a contract as an expense, when incurred, if the amortization period of the asset that the Company otherwise would have recognized is one year or less.

Revenues within the scope of ASC 606 do not include material amounts of variable consideration. Customer payments are generally due in advance of when control is transferred to the customer. The time between invoicing and when payment is due is not significant.

Contract liabilities consist of fees invoiced or paid by the Company's customers for which the associated services have not been performed and revenues have not been recognized based on the Company's revenue recognition criteria described above. Such amounts are reported as deferred revenue on the consolidated balance sheet. Deferred revenue that is expected to be recognized during the following twelve months is recorded as a current liability.

(h) Cost of Sales

Cost of sales consist primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing costs. Cost of sales also includes production and labor costs for the Company's manufacturing business.

(i) Shipping and Handling

The Company records freight billed to customers within Net sales. Shipping and handling costs associated with inbound freight and goods shipped to customers are recorded in cost of sales. Other shipping and handling costs, such as for quality assurance, are recorded in operating expenses.

(j) Recent Accounting Pronouncements Not Yet Adopted

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the consolidated financial statements as a result of future adoption.

**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**3. CUSTOMER CONCENTRATION**

The Company had two customers during the three month period ended March 31, 2022, and three customers during the nine month period ended March 31, 2022, which individually generated 10% or more of the Company's net sales. These customers accounted for 73% and 65% of the Company's sales for the three and nine month period ended March 31, 2022, respectively. As of March 31, 2022, these customers represented 43% of the Company's outstanding accounts receivable.

**4. INVENTORIES**

Inventories consisted of the following:

|                 | March 31,<br>2022 | June 30,<br>2021 |
|-----------------|-------------------|------------------|
|                 | \$                | \$               |
| Work in process | 1,138,566         | -                |
| Finished goods  | 281,816           | -                |
| Inventories     | <u>1,420,382</u>  | <u>-</u>         |

During the three and nine months ended March 31, 2022, inventory expensed to cost of goods sold was \$127,308 and \$280,845 (2021 - \$Nil and \$Nil), respectively.

**5. PROPERTY AND EQUIPMENT, NET**

Property and equipment consisted of the following:

|                                | March 31,<br>2022 | June 30,<br>2021 |
|--------------------------------|-------------------|------------------|
|                                | \$                | \$               |
| Right of Use Asset (leases)    | 1,167,436         | 439,321          |
| Equipment                      | 212,877           | 66,888           |
| Leasehold Improvements         | 40,409            | 42,986           |
| Property and equipment         | <u>1,420,722</u>  | <u>549,195</u>   |
| Less: accumulated depreciation | <u>(417,876)</u>  | <u>(222,600)</u> |
| Property and equipment, net    | <u>1,002,846</u>  | <u>326,595</u>   |

Depreciation expense on property, equipment and leasehold improvements for the three and nine months ended March 31, 2022 was \$7,908 and \$18,371 (2021 - \$3,633 and \$16,546). Depreciation expense related to the Right-of-Use Asset for the three and nine months ended March 31, 2022 was \$89,450 and \$199,058 (2021 - \$22,327 and \$65,506) and was recorded in general and administrative expenses.

**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**6. INTANGIBLE ASSETS, IPR&D AND GOODWILL**

Intangible assets consist of:

|                                | March 31,<br>2022 | June 30,<br>2021 |
|--------------------------------|-------------------|------------------|
|                                | \$                | \$               |
| Intellectual property          | 1,736,420         | 1,736,420        |
| Patents                        | 1,191,000         | -                |
| Trademark                      | 216,000           | -                |
| Intangible assets              | 3,143,420         | 1,736,420        |
| Less: accumulated depreciation | (788,019)         | (674,723)        |
| Intangible assets, net         | <u>2,355,401</u>  | <u>1,061,697</u> |

Acquired intellectual property is recorded at cost and is amortized on a straight-line basis over 18 years.

Acquired patents consist of patents related to the development of cannabinoid analogs. This intangible asset is being amortized over an estimated useful life of 18 years.

The acquired trademark represents the trade name ProDiol® and is being amortized over 10 years.

As at March 31, 2022, the definite-lived intangible assets had a weighted average estimated remaining useful life of approximately 13 years.

Amortization expense on intangible assets for the three and nine months ended March 31, 2022 was \$45,430 and \$113,296 (2021 - \$23,788 and \$75,672). The Company expects amortization expense to be incurred over the next five years as follows:

|      | \$             |
|------|----------------|
| 2022 | 186,062        |
| 2023 | 186,062        |
| 2024 | 186,062        |
| 2025 | 186,062        |
| 2026 | 186,062        |
|      | <u>930,310</u> |

Acquired in-process research and development (IPR&D) are related identifiable intangible assets associated with cannabinoid manufacturing processes and includes \$1,249,000 (2021 – nil) of knowhow and trade secrets acquired in the BayMedica acquisition (see Note 7). Acquired IPR&D represent the fair value assigned to research and development assets that have not reached technological feasibility. IPR&D is classified as an indefinite-lived intangible asset and is not amortized. All research and development costs incurred subsequent to the acquisition of IPR&D are expensed as incurred.

Goodwill of \$2,023,039 (2021 – nil) arose from the acquisition of BayMedica (see Note 7). The Company performs its annual goodwill impairment assessment on June 30, or more frequently if impairment indicators exist. In the event management determines that the value of goodwill has been impaired, the Company will incur an impairment charge during the period in which the determination is made. As of March 31, 2022, there were no indicators of impairment.

**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**7. ACQUISITION**

On October 13, 2021, the Company completed the acquisition of BayMedica, a private company based in the U.S. that specializes in the manufacturing and commercialization of rare cannabinoids. The Company acquired 100% of BayMedica in exchange for i) 2,050,000 common shares issued to BayMedica's equity and convertible debt holders, subject to a six-month contractual hold period and ii) \$1 million to be held in escrow, subject to reduction for certain post-closing adjustments or satisfaction of indemnification claims under the definitive agreement (the "BayMedica Agreement") in the six- and twelve-month periods following the closing.

Total consideration for the acquisition of BayMedica is summarized as follows:

|   | Purchase Price<br>Consideration<br>(\$) |
|---|---|
| Estimated fair value of common shares issued      | 3,013,500                               |
| Cash  | 1,000,000                               |
| Less: Post-closing adjustments                    | (199,543)                               |
| Estimated fair value of consideration transferred | <u>3,813,957</u>                        |

The 2,050,000 common shares were valued at \$1.47, being the closing price of the Company's common shares on Nasdaq on October 12, 2021. The cash component is subject to reduction for certain post-closing adjustments or satisfaction of indemnification claims and therefore is subject to further changes.

In accordance with the acquisition method of accounting, the purchase price of BayMedica has been allocated to the acquired assets and assumed liabilities based on their estimated acquisition date fair values. The fair value estimates were based on income, estimates and other analyses. The excess of the total consideration over the estimated fair value of the amounts initially assigned to the identifiable assets acquired and liabilities assumed has been recorded as goodwill, which is not deductible for income tax purposes. The goodwill balance represents the assembled workforce acquired, the combined company's expectations of the strategic opportunities available as a result of the acquisition, and other synergies that will be derived from the acquisition.

**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**7. ACQUISITION (cont'd)**

The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date:

|   | Purchase Price<br>Allocation<br>(\$) |
|---|--------------------------------------|
| Assets acquired:  |                                      |
| Cash and cash equivalents                                   | 91,566                               |
| Accounts receivable, net of allowance for doubtful accounts | 36,100                               |
| Inventories   | 487,122                              |
| Prepaid expenses and deposits                               | 131,674                              |
| Property and equipment                                      | 133,911                              |
| IPR&D   | 1,249,000                            |
| Patents   | 1,191,000                            |
| Trademark   | 216,000                              |
| Goodwill  | 2,023,039                            |
| Total assets acquired                                       | <u>5,559,412</u>                     |
| Liabilities assumed:  |                                      |
| Accounts payable and accrued liabilities                    | 1,024,487                            |
| Other short-term liabilities                                | 598,245                              |
| Long-term debt  | 122,723                              |
| Total liabilities acquired                                  | <u>1,745,455</u>                     |
| Estimated fair value of net assets acquired                 | <u><u>3,813,957</u></u>              |

Tangible assets and liabilities were valued at their respective carrying amounts as management believes that these amounts approximated their acquisition-date fair values.

The Purchase Price allocation includes certain identifiable intangible assets with an estimated fair value of approximately \$2,656,000. These intangible assets include trade secrets, product formulation knowledge, patents and trademarks. Patents and trademarks are expected to have a finite life and are being amortized using the straight-line method over the respective lives of each asset.

Acquired IPR&D are related identifiable intangible assets associated with cannabinoid manufacturing processes and includes knowhow and trade secrets. The multi-period excess earnings method was used to determine the fair value of these assets as at the date of acquisition. IPR&D is classified as an indefinite-lived intangible asset and is not amortized. All research and development costs incurred subsequent to the acquisition of IPR&D are expensed as incurred.

The acquired trademark represents the trade name ProDiol®. The fair value of the trademark, which was determined using the relief from royalty method, was capitalized as of the acquisition date and is subsequently being amortized over 10 years.



**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS****FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021**

(Expressed in U.S. Dollars)

**7. ACQUISITION (cont'd)**

Acquired patents consist of patents related to the development of cannabinoid analogs, the fair value of which was determined using the income approach. This intangible asset is being amortized over an estimated useful life of 18 years.

As of March 31, 2022, the Company had not yet fully completed the analysis to assign fair values to all assets acquired and liabilities assumed, and therefore the purchase price allocation is preliminary. The remaining items include the finalization of working capital, income taxes and resulting impacts to goodwill. The preliminary purchase price allocation will be subject to further refinement as the Company continues to refine its estimates and assumptions based on information available at the acquisition date. The purchase price allocation adjustments can be made throughout the end of the Company's measurement period, which is not to exceed one year from the acquisition date.

Following the acquisition date, the operating results of BayMedica have been included in the unaudited condensed consolidated financial statements. For the period from the October 13, 2021 acquisition date through March 31, 2022, sales attributable to BayMedica were \$0.6 million and operating losses attributable to BayMedica were \$1.8 million. Acquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled \$0.2 million for the nine months ended March 31, 2022 and were included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.

The following table presents the pro forma consolidated results of the Company assuming the BayMedica acquisition had been completed on July 1, 2020:

|          | Three Months Ended |             | Nine Months Ended |             |
|----------|--------------------|-------------|-------------------|-------------|
|          | March 31           |             | March 31          |             |
|          | 2022               | 2021        | 2022              | 2021        |
|          | \$                 | \$          | \$                | \$          |
| Sales    | 309,585            | 437,309     | 574,677           | 1,023,379   |
| Net loss | (3,390,440)        | (3,600,787) | (10,468,072)      | (8,653,636) |

**8. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES**

Accounts payable and accrued liabilities consist of the following:

|  | March 31, | June 30,  |
|--|-----------|-----------|
|  | 2022      | 2021      |
|  | \$        | \$        |
| Trade payables                                       | 1,676,179 | 775,129   |
| Accrued research and development expenses            | 364,207   | 309,901   |
| Employee compensation, benefits and related accruals | 711,421   | 880,207   |
| Accrued general and administrative expenses          | 115,120   | 169,641   |
| Accounts payable and accrued liabilities             | 2,866,927 | 2,134,878 |

**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**9. SHARE CAPITAL AND RESERVES**

## a) Authorized

As at March 31, 2022, the Company's authorized share structure consisted of: (i) an unlimited number of common shares without par value; and (ii) an unlimited number of preferred shares without par value. No preferred shares were issued and outstanding as at March 31, 2022 and June 30, 2021.

The Company may issue preferred shares and may, at the time of issuance, determine the rights, preference and limitations pertaining to these shares. Holders of preferred shares may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding up of the Company before any payment is made to the holders of common shares.

## b) Common Shares

During the nine months ended March 31, 2022, the Company completed the following private placement:

| <b>Transaction Description</b>          | <b>Number</b> | <b>Issue Price</b> | <b>Total</b>  |
|---|---------------|--------------------|---------------|
| Private placement - Shares              | 890,000       | \$ 2.973           | \$ 2,645,970  |
| Private placement - Pre-funded warrants | 3,146,327     | \$ 2.9729          | 9,353,716     |
| Gross Proceeds                          |               |                    | \$ 11,999,686 |
| Allocated to Additional Paid-in Capital |               |                    | (10,540,635)  |
|   |               |                    | \$ 1,459,051  |
| Share issuance costs                    |               |                    | \$ (247,336)  |

On July 2, 2021, the Company closed a private placement of its common shares and issued an aggregate of 890,000 common shares and 3,146,327 pre-funded warrants, for gross proceeds of \$11,999,686. The pre-funded warrants were determined to be common stock equivalents. Each common share and each pre-funded warrant was sold in the offering with a warrant to purchase a common share. Transaction costs were allocated proportionally between common shares and warrants with \$247,336 allocated to common shares and the balance of \$1,786,831 allocated to additional paid-in capital and recorded as a component of shareholders' equity in the consolidated balance sheet. The 3,146,327 pre-funded warrants were fully exercised for 3,146,327 common shares during the nine months ended March 31, 2022 resulting in a \$4,283,654 reclassification from additional paid-in capital to common shares.

During the nine months ended March 31, 2022, in accordance with the BayMedica Agreement, the Company issued 2,050,000 common shares to BayMedica's historical equity and convertible debt holders (See Note 7).

## c) Share Purchase Warrants

On November 16, 2020, 1,780,000 warrants were issued with an exercise price of \$5.11 per share, were immediately exercisable upon issuance, and expire 6 years following the date of issuance.

**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**9. SHARE CAPITAL AND RESERVES (cont'd)**

## (c) Share Purchase Warrants (cont'd)

On February 12, 2021, 693,000 warrants were issued with an exercise price of \$4.85 per share, were exercisable 6 months following issuance, and expire 5.5 years following the date of issuance. On March 21, 2022, the Company amended the warrants to re-price them to \$0.45 per share with an expiry date of March 31, 2023. Between March 21, 2022 and March 31, 2022, 369,600 of the warrants were exercised on a cashless basis resulting in the issuance of 146,814 common shares.

On July 2, 2021, 4,036,327 warrants were issued with an exercise price of \$2.848 per share, were immediately exercisable upon issuance, and expire 5 years following the date of issuance. The pre-funded and common warrants did not meet the criteria to be classified as a liability award and therefore were treated as an equity award and recorded as a component of shareholders' equity in the consolidated balance sheet.

The following is a summary of changes in share purchase warrants from July 1, 2021 to March 31, 2022:

|                              | Number           | Weighted<br>Average<br>Share Price | Aggregate<br>Intrinsic<br>Value |
|------------------------------|------------------|------------------------------------|---------------------------------|
| Balance as at June 30, 2021  | 2,473,000        | \$ 3.80                            | -                               |
| Granted                      | 4,036,327        | \$ 2.848                           | -                               |
| Exercised                    | (369,600)        | \$ 0.45                            | 114,716                         |
| Balance as at March 31, 2022 | <u>6,139,727</u> | <u>\$ 3.38</u>                     | <u>-</u>                        |

The total intrinsic value of warrants exercised during the quarter ended March 31, 2022 was \$114,716 (2021 - \$Nil).

## d) Agents' Warrants

On July 2, 2021, 302,725 warrants were issued for services with an exercise price of \$3.7163 per share, were immediately exercisable upon issuance, and expire 5 years following the date of issuance. The agents' warrants did not meet the criteria to be classified as a liability award and therefore were treated as an equity award and recorded as a component of shareholders' equity in the consolidated balance sheet.

The following is a summary of changes in agents' warrants from July 1, 2021 to March 31, 2022:

|                              | Number         | Weighted<br>Average<br>Share Price | Aggregate<br>Intrinsic<br>Value |
|------------------------------|----------------|------------------------------------|---------------------------------|
| Balance as at June 30, 2021  | -              | -                                  | -                               |
| Granted                      | 302,725        | \$ 3.7163                          | -                               |
| Balance as at March 31, 2022 | <u>302,725</u> | <u>\$ 3.7163</u>                   | <u>-</u>                        |

**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**10. SHARE-BASED PAYMENTS**

## a) Option Plan Details

On March 24, 2017, and as amended on November 20, 2020, the Company's shareholders approved: (i) the adoption of a new stock option plan (the "Plan") pursuant to which the Board of Directors may, from time to time, in its discretion and in accordance with regulatory requirements, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed twenty percent (20%) of the issued and outstanding common shares at the date the options are granted (on a non-diluted and rolling basis); and (ii) the application of the new stock option plan to all outstanding stock options of the Company that were granted prior to March 24, 2017 under the terms of the Company's previous stock option plan.

As at March 31, 2022, there were 420,165 (June 30, 2021 – 493,387) options available for future allocation pursuant to the terms of the Plan. The option price under each option shall be not be less than the closing price on the day prior to the date of grant. All options vest upon terms as set by the Board of Directors, either over time, typically 12 to 36 months, or upon the achievement of certain corporate milestones.

Stock options granted prior to May 2021 were granted with Canadian dollar exercise prices (United States dollar amounts for weighted average exercise prices and aggregate intrinsic value are calculated using prevailing rates as at March 31, 2022). Commencing in May 2021, stock options are granted with United States dollar exercise prices.

The following is a summary of changes in outstanding options from July 1, 2021 to March 31, 2022:

|                                     | Number           | Weighted<br>Average<br>Exercise<br>Price<br>\$ |
|-------------------------------------|------------------|--|
| Balance as at June 30, 2021         | 912,006          | 8.61   |
| Granted                             | 765,000          | 1.38   |
| Expired/Forfeited                   | (267,463)        | 4.24   |
| <b>Balance as at March 31, 2022</b> | <b>1,409,543</b> | <b>5.40</b>                                    |
| <b>March 31, 2022:</b>              |                  |  |
| Vested and exercisable              | 479,249          | 12.57  |
| Unvested                            | 930,294          | 1.71   |

**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**10. SHARE-BASED PAYMENTS (cont'd)**

## b) Fair Value of Options Issued During the Period

## i) Weighted Average Fair Value at Grant Date of Options Granted:

The weighted average fair value at grant date of options granted during the nine months ended March 31, 2022, was \$1.38 per option (year ended June 30, 2021 - \$1.96). Assumptions used for options granted during the nine months ended March 31, 2022 included a weighted average risk-free interest rate of 1.14% (year ended June 30, 2021 - 0.27%), weighted average expected life of 3.1 years calculated using the Simplified Method for directors, officers and employees and the contractual life for consultants, weighted average volatility factor of 97.26% (year ended June 30, 2021 - 105.88%), weighted average dividend yield of 0% (year ended June 30, 2021 - 0%) and a 5% forfeiture rate (year ended June 30, 2021 - 5%).

## ii) Expenses Arising from Share-based Payment Transactions:

Total expenses arising from share-based payment transactions recognized during the three months ended March 31, 2022, were \$195,085 (2021 - \$207,302). \$103,401 was allocated to general and administrative expenses (2021 - \$138,880) and the remaining \$91,684 was allocated to research and development expenses (2021 - \$68,422). Total expenses arising from share-based payment transactions recognized during the nine months ended March 31, 2022, were \$521,006 (2021 - \$389,343). \$307,885 was allocated to general and administrative expenses (2021 - \$248,836) and the remaining \$213,121 was allocated to research and development expenses (2021 - \$140,507). Unrecognized compensation cost at March 31, 2022 related to unvested options was \$431,558 which will be recognized over a weighted-average vesting period of 1.2 years.

**11. LEASE OBLIGATIONS**

On commencement of a lease on July 1, 2019, the Company recognized right-of-use assets of \$434,660 and a lease liability of \$385,057 with no net impact on accumulated deficit.

In conjunction with the acquisition of BayMedica (Note 7), the Company acquired an operating lease for a corporate office with a remaining term of 2.1 years as at March 31, 2022. On the date of acquisition of BayMedica, the Company recognized right-of-use assets of \$728,115 and a lease liability of \$825,427, utilizing the remaining term on acquisition and a 4.0% discount rate.

The Company is committed to minimum lease payments as follows:

| Maturity Analysis                    | March 31,<br>2022           |
|--------------------------------------|-----------------------------|
| Less than one year                   | \$ 431,680                  |
| One to five years                    | 845,291                     |
| More than five years                 | -                           |
| Total undiscounted lease liabilities | \$ 1,276,971 <sup>(1)</sup> |

(1) Excludes estimated variable operating costs of \$92,677 and \$62,824 on an annual basis through to April 30, 2024 and August 31, 2024, respectively.

**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**12. BASIC AND DILUTED LOSS PER SHARE**

Basic loss per share amounts are calculated by dividing the net loss for the period by the weighted average number of ordinary shares outstanding during the period. The pre-funded warrants were determined to be common stock equivalents and have been included in the weighted average number of shares outstanding for calculation of the basic earnings per share number. As the outstanding stock options and warrants are anti-dilutive, they are excluded from the weighted average number of common shares in the table below.

|  | Three Months Ended |             | Nine Months Ended |             |
|--|--------------------|-------------|-------------------|-------------|
|  | March 31,          |             | March 31,         |             |
|  | 2022               | 2021        | 2022              | 2021        |
|  | \$                 | \$          | \$                | \$          |
| Net loss for the period                                      | (3,475,665)        | (3,101,475) | (10,730,094)      | (6,944,336) |
| Basic and diluted loss per share                             | (0.25)             | (0.41)      | (0.81)            | (1.11)      |
| Weighted average number of common shares - basic and diluted | 14,151,544         | 7,549,040   | 13,326,754        | 6,277,824   |

**13. SEGMENT INFORMATION**

As of the closing of the BayMedica acquisition, the Company aligned into two operating and reportable segments, InMed Pharmaceuticals (the “InMed” segment) and BayMedica (the “BayMedica” segment). The Company reports segment information based on the management approach which designates the internal reporting used by the Chief Operating Decision Maker (“CODM”), which is the Company’s Chief Executive Officer, for making decisions and assessing performance as the source of the Company’s reportable segments. The CODM allocates resources and assesses the performance of each operating segment based on potential licensing opportunities, historical and potential future product sales, operating expenses, and operating income (loss) before interest and taxes. The Company has determined its reportable segments to be InMed and BayMedica based on the information used by the CODM. Other than cash, cash equivalents and short-term investments (“Unrestricted cash”) balances, the CODM does not regularly review asset information by reportable segment and therefore, the Company does not report asset information by reportable segment.

The InMed segment is largely organized around the research and development of cannabinoid-based pharmaceuticals products and the BayMedica segment is largely organized around developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry.

**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**13. SEGMENT INFORMATION (cont'd)**

The following table presents information about the Company's reportable segments for the three and nine months ended March 31, 2022 and 2021:

|                    | Three Months Ended March 31, |           |                    |             |           |                    |
|--------------------|------------------------------|-----------|--------------------|-------------|-----------|--------------------|
|                    | 2022                         |           |                    | 2021        |           |                    |
|                    | InMed                        | BayMedica | Total              | InMed       | BayMedica | Total              |
|                    |                              | \$        | \$                 | \$          | \$        | \$                 |
| Sales              | -                            | 309,585   | <b>309,585</b>     | -           | -         | -                  |
| Operating expenses | 2,940,961                    | 844,289   | <b>3,785,250</b>   | 3,101,475   | -         | <b>3,101,475</b>   |
| Net loss           | (2,940,961)                  | (534,704) | <b>(3,475,665)</b> | (3,101,475) | -         | <b>(3,101,475)</b> |
| Unrestricted cash  | 5,386,206                    | 512,107   | <b>5,898,313</b>   | 9,454,113   | -         | <b>9,454,113</b>   |

  

|                    | Nine Months Ended March 31, |             |                     |             |           |                    |
|--------------------|-----------------------------|-------------|---------------------|-------------|-----------|--------------------|
|                    | 2022                        |             |                     | 2021        |           |                    |
|                    | InMed                       | BayMedica   | Total               | InMed       | BayMedica | Total              |
|                    |                             | \$          | \$                  | \$          | \$        | \$                 |
| Sales              | -                           | 574,677     | <b>574,677</b>      | -           | -         | -                  |
| Operating expenses | 9,477,441                   | 1,827,330   | <b>11,304,771</b>   | 6,944,336   | -         | <b>6,944,336</b>   |
| Net loss           | (9,477,441)                 | (1,252,653) | <b>(10,730,094)</b> | (6,944,336) | -         | <b>(6,944,336)</b> |
| Unrestricted cash  | 5,386,206                   | 512,107     | <b>5,898,313</b>    | 9,454,113   | -         | <b>9,454,113</b>   |

**14. NON-CASH TRANSACTIONS**

Investing and financing activities that do not have a direct impact on cash flows are excluded from the statements of cash flows. During the nine months ended March 31, 2022, the following transactions were excluded from the statement of cash flows:

- i) On July 2, 2021, the Company issued warrants to its placement agent. The fair value of these warrants was \$739,920 and was included in share issuance costs related to the July 2021 private placement.
- ii) On October 13, 2021, the Company issued 2,050,000 common shares to BayMedica's equity and convertible debt holders, pursuant to the BayMedica Agreement. The estimated fair value of these common shares was \$3,013,500 and was included in the total consideration for the acquisition of BayMedica (see Note 7).
- iii) 369,600 warrants were exercised on a cashless basis resulting in the issuance of 146,814 common shares.

During the nine months ended March 31, 2021, the following transaction was excluded from the statement of cash flows:

- i) As at March 31, 2021, the Company has unpaid financing costs of \$138,927.

**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**15. COMMITMENTS AND CONTINGENCIES**

Pursuant to the terms of agreements with various contract research organizations, as at March 31, 2022, the Company is committed for contract research services and materials at a cost of approximately \$3,319,699. A total of \$3,209,699 of these expenditures are expected to occur in the twelve months following March 31, 2022 and the balance of \$110,000 in the following twelve month period.

Pursuant to the terms of a May 31, 2017 Technology Assignment Agreement between the Company and the University of British Columbia ("UBC"), the Company is committed to pay royalties to UBC on certain licensing and royalty revenues received by the Company for biosynthesis of certain drug products that are covered by the agreement. To date, no payments have been required to be made.

Pursuant to the terms of a December 13, 2018 Collaborative Research Agreement with UBC in which the Company owns all rights, title and interests in and to any intellectual property, in addition to funding research at UBC, the Company is committed to make a one-time payment upon filing of any PCT patent application arising from the research. To date, one such payment has been made to UBC.

Pursuant to the terms of a November 1, 2018 Contribution Agreement with National Research Council Canada, as represented by its Industrial Research Assistance Program (NRC-IRAP), under certain circumstances contributions received, including the disposition of the underlying intellectual property developed in part with NRC-IRAP contributions, may become repayable.

Short-term investments include guaranteed investment certificates with a face value of \$46,017 (June 30, 2021 - \$46,391) that are pledged as security for a corporate credit card.

The Company has entered into certain agreements in the ordinary course of operations that may include indemnification provisions, which are common in such agreements. In some cases, the maximum amount of potential future indemnification is unlimited; however, the Company currently holds commercial general liability insurance. This insurance limits the Company's liability and may enable the Company to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and it believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

Pursuant to a technology licensing agreement, the Company is committed to issue, subject to regulatory approval, up to 17,500 warrants to purchase 17,500 common shares upon the achievement of certain milestones. The exercise price of the warrants will be equal to the five-day VWAP of the common shares prior to each milestone achievement and the warrants will be exercisable for a period of three years for issuance date.

The Company entered into a patent license agreement with a third party (the "Licensor") in an agreement dated February 15, 2021. The Company is required to make future royalty payments to Licensor based on net sales of licensed products, with minimum payments required starting in 2021. In December 2021, the Company amended the License Agreement including the deferral of the 2021 minimum payments to 2022. As at March 31, 2022, the Company has accrued \$300,000 for the minimum payments under the agreement.

From time to time, the Company may be subject to various legal proceedings and claims related to matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.



**INMED PHARMACEUTICALS INC.**

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

**FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021**

(Expressed in U.S. Dollars)

---

**16. FINANCIAL RISK MANAGEMENT**

The Company's financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued liabilities.

The fair values of short-term investments, accounts receivable, and accounts payable and accrued liabilities approximate their carrying values because of the short-term nature of these instruments. Cash and cash equivalents are measured at fair value using Level 1 inputs.

a) **Market Risk:**

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices are comprised of four types of risk: foreign currency risk, interest rate risk, commodity price risk and equity price risk. The Company does not currently have significant commodity price risk or equity price risk.

*Foreign Currency Risk:*

Foreign currency risk is the risk that the future cash flows or fair value of the Company's financial instruments that are denominated in a currency that is not the Company's functional currency (U.S. dollar) will fluctuate due to changes in foreign exchange rates. Portions of the Company's cash and cash equivalents and accounts payable and accrued liabilities are denominated in Canadian dollars.

Accordingly, the Company is exposed to fluctuations in exchange rates, primarily against the Canadian dollar.

As at March 31, 2022, the Company has a net excess of Canadian dollar denominated cash and cash equivalents in excess of Canadian dollar denominated accounts payable and accrued liabilities of C\$1,572,337 which is equivalent to US\$1,258,342 at the March 31, 2022 exchange rate. The Canadian dollar financial assets generally result from holding Canadian dollar cash to settle anticipated near-term accounts payable and accrued liabilities denominated in Canadian dollars. The Canadian dollar financial liabilities generally result from purchases of supplies and services from suppliers in Canada.

Each change of 1% in the Canadian dollar in relation to the U.S. dollar results in a gain or loss, with a corresponding effect on cash flows, of \$12,583 based on the March 31, 2022 net Canadian dollar assets (liabilities) position. During the nine months ended March 31, 2022, the Company recorded foreign exchange loss of \$35,228 (2021 – \$30,385) related to Canadian dollars.

*Interest Rate Risk:*

Interest rate risk is the risk that future cash flows will fluctuate as a result of changes in market interest rates. As at March 31, 2022, holdings of cash and cash equivalents of \$4,483,590 (June 30, 2021 - \$7,053,329) are subject to floating interest rates. The balance of the Company's cash holdings of \$1,414,723 (June 30, 2021 - \$309,796) are non-interest bearing.

As at March 31, 2022, the Company held variable rate guaranteed investment certificates, with one-year terms, of \$46,098 (June 30, 2021 - \$46,462).

The Company's current policy is to invest excess cash in guaranteed investment certificates or interest-bearing accounts of major Canadian chartered banks or credit unions with comparable credit ratings. The Company regularly monitors compliance to its cash management policy.

**INMED PHARMACEUTICALS INC.****NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE AND NINE MONTHS ENDED MARCH, 2022 AND 2021

(Expressed in U.S. Dollars)

**16. FINANCIAL RISK MANAGEMENT (cont'd)**

## b) Credit Risk:

Credit risk is the risk of financial loss to the Company if a customer or a counter party to a financial instrument fails to meet its contractual obligations. Financial instruments which are potentially subject to credit risk for the Company consist primarily of cash and cash equivalents, short-term investments and loan receivable. Cash and cash equivalents and short-term investments are maintained with financial institutions of reputable credit and may be redeemed upon demand. In the normal course of business, the Company does not provide third party loans.

The carrying amount of financial assets represents the maximum credit exposure. Credit risk exposure is limited through maintaining cash and cash equivalents and short-term investments with high-credit quality financial institutions and management considers this risk to be minimal for all cash and cash equivalents and short-term investments assets based on changes that are reasonably possible at each reporting date.

## c) Liquidity Risk:

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company's policy is to ensure that it has sufficient cash to meet its liabilities when they become due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. A key risk in managing liquidity is the degree of uncertainty in the cash flow projections. If future cash flows are fairly uncertain, the liquidity risk increases. As at March 31, 2022, the Company has cash and cash equivalents and short-term investments of \$5,944,411 (June 30, 2021 - \$7,409,588), current liabilities of \$4,105,502 (June 30, 2021 - \$2,215,361) and a working capital surplus of \$4,641,384 (June 30, 2021 - \$6,162,908).

**17. RELATED PARTY TRANSACTIONS**

On February 11, 2022, the Board of Directors appointed Janet Grove as a director of the Company. There were no arrangements nor understandings with Ms. Grove pursuant to which she was selected as a director of the Company, and there were no family relationship between Ms. Grove and any of the Company's other directors or executive officers. Ms. Grove is a Partner of Norton Rose Fulbright Canada LLP ("NRF"). From February 11, 2022 to March 31, 2022, NRF rendered legal services in the amount of \$27,770 (2021 - \$Nil) to the Company. These transactions were in the normal course of operations and were measured at the exchange amount which represented the amount of consideration established and agreed to by NRF.

**18. SUBSEQUENT EVENTS**

On April 21, 2022, 20,556 of the February 2021 warrants were exercised on a cashless basis resulting in the issuance of 10,556 common shares.

On April 13, 2022, in accordance with the BayMedica Agreement, \$300,457 of escrow payments were made to BayMedica's historical equity and convertible debt holders reflecting \$199,543 of post-closing reductions from the escrow. The remaining \$500,000 escrow payment, subject to any additional post-closing adjustments, is payable on the twelve-month anniversary following the closing.

On April 7, 2022, the Company filed a prospectus supplement to its S-3 universal shelf filing to incorporate an At The Market Offering Agreement following which the Company sold 268,985 common shares under the agreement with net proceeds of \$0.3 million.

## CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities law, which are included but are not limited to statements with respect to InMed Pharmaceuticals Inc.’s (the “Company” or “InMed”) anticipated results and progress of the Company’s operations, research and development in future periods, plans related to its business strategy, and other matters that may occur in the future. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. We may, in some cases, use words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “will”, “would”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Form 10-Q include, but are not limited to, statements about:

- Our researching, developing, manufacturing and commercializing cannabinoid-based biopharmaceutical products will treat diseases with high unmet medical needs;
- Bringing strict scientific discipline to the field of cannabinoid medicine;
- Serving as a business-to-business (B2B) supplier to wholesalers and end-product manufacturers / marketers in the health and wellness sector;
- Our ability to register and commercialize Product Candidates in the United States and other jurisdictions;
- The future timing of INM-755 and INM-088 studies and research into potential new uses;
- Our ability to source required materials from third-party manufacturers;
- Our ability to successfully integrate and develop BayMedica’s operations and expand the BayMedica Product portfolio;
- Our ability to successfully develop and scale-up our manufacturing approaches including our ability transfer to a contract development and manufacturing organization, or “CDMO”;
- Our ability to transfer our integrative biosynthesis-based manufacturing approach”;
- Our ability to deliver our rare cannabinoid pharmaceuticals through various topical formulations (cream for dermatology, eye drops for ocular diseases);
- Our ability to minimize systemic exposure and any related unwanted systemic side effects, including any drug-drug interactions and any metabolism of the active pharmaceutical ingredient by the liver;

- Our ability to continue development of INM-755, our lead drug candidate for the treatment of EB, and the development of INM-088, our drug candidate for the treatment of glaucoma;
- Our ability to pursue the discovery of drug targets for other diseases with high unmet medical needs and the subsequent development of any resulting Product Candidates;
- Our ability to seek regulatory approvals for any Product Candidates that successfully complete clinical trials;
- Our ability to scale-up our manufacturing processes and capabilities, or arrange for a third party to do so on our behalf;
- Acquiring or in-licensing externally developed products and/or technologies;
- Maintaining, expanding, enforcing, defending and protecting our intellectual property;
- Our ability to hire additional clinical, quality control, sales and scientific personnel;
- Our ability to add operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and our operations as a public company; and
- Our ability to finance our operations through product sales, the sale of equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions.

This list is not exhaustive of the factors that may affect our forward-looking statements. Some of the important risks and uncertainties that could affect forward-looking statements are described further under the section heading: Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations of this report. Although we have attempted to identify important factors that could cause actual results to differ materially from those described in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated, or expected. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made and are based only on the information available to us at that time. Except as required by law, we disclaim any obligation to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

**ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.**

**InMed Pharmaceuticals Inc.**  
**MANAGEMENT’S DISCUSSION AND ANALYSIS**  
**Three and nine months ended March 31, 2022**

---



**InMed Pharmaceuticals Inc.**

**MANAGEMENT’S DISCUSSION AND ANALYSIS**  
**OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS**

**Three and Nine Months Ended**

**March 31, 2022**

*This discussion and analysis contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is subject to the safe harbor created by those sections. For more information, see “Cautionary Note Regarding Forward-Looking Statements.” When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that impact our business. In particular, we encourage you to review the risks and uncertainties described in “Risk Factors” in our Annual Report on Form 10-K, dated September 24, 2021, and other filings with the Security and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from those projected or implied by our forward-looking statements contained in this report. These forward-looking statements are made as of the date of this report, and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law.*

*The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated interim financial statements for the three and nine months ended March 31, 2022, and the related notes thereto, which have been prepared in accordance with U.S. GAAP. Additionally, the following discussion and analysis should be read in conjunction with our audited consolidated financial statements included in our Form 10-K filing. Throughout this discussion, unless the context specifies or implies otherwise, the terms “InMed,” “Company,” “we,” “us,” and “our” refer to InMed Pharmaceuticals Inc.*

*All dollar amounts stated herein are in U.S. dollars unless specified otherwise.*

**Overview**

We are a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with our subsidiary BayMedica, LLC, we have unparalleled cannabinoid manufacturing capabilities and technologies to produce rare cannabinoids for sale in the health and wellness industry (“Products”). We are also a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs (“Product Candidates”).

We are developing multiple manufacturing approaches for synthesizing rare cannabinoids for potential use in pharmaceutical Product Candidates as well as serving as a business-to-business (B2B) supplier to wholesalers and end-product manufacturers / marketers in the health and wellness sector. This includes traditional approaches such as chemical synthesis and biosynthesis, as well as a proprietary, integrated manufacturing approach called IntegraSyn™. We are dedicated to delivering new therapeutic alternatives to patients and consumers who may benefit from cannabinoid-based products. Our approach leverages on the several thousand years' history of health benefits attributed to the *Cannabis* plant and brings this anecdotal information into the 21st century by applying tried, tested and true scientific approaches to establish non-plant-derived (synthetically manufactured), individual cannabinoid compounds as Product Candidates in important market segments including clinically proven, FDA-approved medicines and non-prescription, over-the-counter consumer products via B2B supply relationships with wholesalers and end-product manufacturers. While our activities do not involve direct use of *Cannabis* nor extracts from the plant, we note that the U.S. Food and Drug Administration ("FDA") has, to date, not approved any marketing application for *Cannabis* for the treatment of any disease or condition and has approved only one *Cannabis*-derived and three *Cannabis*-related drug products. Our ingredients are synthetically made and, therefore, we have no interaction with the *Cannabis* plant. We do not grow nor utilize *Cannabis* nor its extracts in any of our Products or Product Candidates; our current pharmaceutical drug Product Candidates are applied topically (not inhaled nor ingested); and, we do not utilize THC or CBD, the most common cannabinoid compounds that are typically extracted from the *Cannabis* plant, in any of our Products or Product Candidates. The active pharmaceutical ingredient ("API") under development for our initial two drug candidates, INM-755 for Epidermolysis bullosa ("EB") and INM-088 for glaucoma, is cannabidiol ("CBD"). Additional uses of both INM-755 and INM-088 are being explored, as well as the application of additional rare cannabinoids to treat diseases including but not limited to neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's.

We believe we are positioned to develop multiple pharmaceutical Product Candidates in diseases which may benefit from medicines based on rare cannabinoid compounds. Most currently approved cannabinoid therapies are based specifically on CBD and/or THC and are often delivered orally, which has limitations and drawbacks, such as side effects (including the intoxicating effects of THC). Currently, we intend to deliver our rare cannabinoid pharmaceutical drug candidates through various topical formulations (cream for dermatology, eye drops for ocular diseases) as a way of enabling treatment of the specific disease at the site of disease while seeking to minimize systemic exposure and any related unwanted systemic side effects, including any drug-drug interactions and any metabolism of the active pharmaceutical ingredient by the liver. The cannabinoids sold through our B2B raw material supply business are integrated into various product formats by the companies who then further commercializes such products. We plan to access rare cannabinoids via all non-extraction approaches, including chemical synthesis, biosynthesis and our proprietary integrated IntegraSyn™ approach, thus negating any interaction with or exposure to the *Cannabis* plant.

Since our acquisition of Biogen Sciences Inc., a privately held British Columbia pharmaceutical company focused on drug discovery and development of cannabinoids in 2014, our operations have focused on conducting research and development for our Product Candidates and for our integrated, biosynthesis-based manufacturing technology, establishing our intellectual property, organizing and staffing our Company, business planning and capital raising. On October 13, 2021, we acquired BayMedica, Inc., now named BayMedica, LLC ("BayMedica"). Upon closing of the transaction, BayMedica became a wholly-owned subsidiary of InMed. To date, we have funded our operations primarily through the issuance of common shares.

We have incurred significant operating losses since our inception and since the acquisition of Biogen Science Inc. and we expect to continue to incur significant operating losses for the foreseeable future. Our ability to generate product revenue, if ever, that is sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our drug candidates and/or the success of our manufacturing technologies. Our net loss was \$10.7 million and \$6.9 million for the nine months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, we had an accumulated deficit of \$85.6 million, which includes all losses since our inception in 1981. Our accumulated deficit increased between 2014, when we began focusing on the development of cannabinoid-derived pharmaceuticals following the acquisition of Biogen Science Inc., and March 31, 2022 by approximately \$56.7 million. We expect our expenses and operating losses will increase substantially over the next several years in connection with our ongoing activities as we:

- continue to further advance the development of our manufacturing technologies;

- continue to further advance the INM-755 program, our lead drug candidate for the treatment of EB;
- expand our BayMedica Product portfolio;
- continue to further advance the INM-088 program, our drug candidate for the treatment of glaucoma;
- investigate our Product Candidates for additional uses beyond the initial indications;
- pursue the discovery of drug targets for other diseases with high unmet medical needs and the subsequent development of any resulting new Product Candidates;
- seek regulatory approvals for any Product Candidates that successfully complete clinical trials;
- scale-up our manufacturing processes and capabilities, or arrange for a third party to do so on our behalf;
- execute on business development activities, including but not limited to company mergers/acquisitions and acquisition or in-licensing of externally developed products and/or technologies;
- maintain, expand, enforce, defend and protect our intellectual property;
- hire additional clinical, quality control, sales and scientific personnel; and
- add operational, financial and management information systems and personnel, including personnel to support product development and potential future commercialization efforts and our operations as a public company.

As a result of these activities as well as our working capital requirements, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through product sales, the sale of equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our Products and Product Candidates or grant rights to external entities to develop and market our Product Candidates, even if we would otherwise prefer to develop and market such Products and Product Candidates ourselves.

Because of the numerous risks and uncertainties associated with drug development and commercial growth, we are unable to predict the timing or amount of increased expenses and working capital requirements or the timing of when or if we will be able to achieve or maintain profitability. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

### **Recent Developments**

On July 2, 2021, we closed a \$12.0 million private placement. After deducting the placement agent fees and estimated offering expenses payable by the Company, we received net proceeds of approximately \$11.0 million.

On September 30, 2021, we announced that we commenced our Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa ("EB") marking the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease.

On October 13, 2021, we completed the acquisition of BayMedica Inc. ("BayMedica"), a private company based in the U.S. that specializes in the manufacturing and commercialization of rare cannabinoids. We acquired 100% of BayMedica in exchange for 2.05 million common shares issued to BayMedica's equity and convertible debt holders, subject to a six-month contractual hold period and \$1 million to be held in escrow, subject to reduction for certain post-closing adjustments or satisfaction of indemnification claims under the definitive agreement in the six- and twelve-month periods following the closing. On April 13, 2022, \$300,457 of escrow payments were made to BayMedica's historical equity and convertible debt holders reflecting \$199,543 of post-closing reductions from the escrow. The remaining \$500,000 escrow payment, subject to any additional post-closing adjustments, is payable on the twelve-month anniversary following the closing.

We announced the launch B2B sales of the rare cannabinoids cannabicitran ("CBT") and cannabidivarin ("CBDV") on January 19, 2022 and on April 21, 2022, respectively.

### **Components of Results of Operations**

#### *Revenue*

Our revenue consists of manufacturing and distribution sales of bulk rare cannabinoids, which are generally recognized at a point in time when control over the products have been transferred to the customer.

#### *Cost of Sales*

Cost of sales consist primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing costs. Cost of sales also includes production and labor costs for our manufacturing business.

#### *Operating Expenses*

##### *Research and Development and Patent Expenses*

Research and development and patent expenses represent costs incurred by us for the discovery, development, and manufacture of our Products and Product Candidates and include:

- external research and development expenses incurred under agreements with contract research organizations, or "CROs", contract development and manufacturing organization, or "CDMOs", and consultants;
- salaries, payroll taxes, employee benefits expenses for individuals involved in research and development efforts;



- research supplies; and
- legal and patent office fees related to patent and intellectual property matters.

We expense research and development costs as incurred. We recognize expenses for certain development activities, such as preclinical studies and manufacturing, based on an evaluation of the progress to completion of specific tasks using data or other information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of expenses incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. These amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.

External costs represent a significant portion of our research and development expenses, which we track on a program-by-program basis following the nomination of a development candidate. Our internal research and development expenses consist primarily of personnel-related expenses, including salaries, benefits and stock-based compensation expense. We do not track our internal research and development expenses on a program-by-program basis as the resources are deployed across multiple projects.

The successful development of our Products and Product Candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the remainder of the development of our Product Candidates or to develop and commercialize additional Products. We are also unable to predict when, if ever, material net cash inflows will commence from our Product Candidates, if approved. This is due to the numerous risks and uncertainties associated with development, including the uncertainty related to:

- the timing and progress of preclinical and clinical development activities;
- the number and scope of preclinical and clinical programs we decide to pursue;
- our ability to raise additional funds necessary to develop and commercialize additional Products, to complete preclinical and clinical development and commercialization of our Product Candidates and to further advance the development of our manufacturing technologies;
- our ability to maintain our current research and development programs and to establish new ones;
- our ability to establish sales, licensing or collaboration arrangements;
- the progress of the development efforts of parties with whom we may enter into collaboration arrangements;
- the successful initiation and completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority;
- the receipt and related terms of regulatory approvals from applicable regulatory authorities;
- the availability of materials for use in production of our Products and Product Candidates;
- our ability to secure manufacturing supply through relationships with third parties or establish and operate a manufacturing facility;
- our ability to consistently manufacture our Product Candidates in quantities sufficient for use in clinical trials;

- our ability to obtain and maintain intellectual property protection and regulatory exclusivity, both in the United States and internationally;
- our ability to maintain, enforce, defend and protect our rights in our intellectual property portfolio;
- the commercialization of our Product Candidates, if and when approved, and of new Products;
- our ability to obtain and maintain third-party payor coverage and adequate reimbursement for our Product Candidates, if approved;
- the acceptance of our Product Candidates, if approved, by patients, the medical community and third-party payors;
- competition with other products; and
- a continued acceptable safety profile of our Product Candidates following receipt of any regulatory approvals.

A change in the outcome of any of these variables with respect to the development of any of our Product or Product Candidates would significantly change the costs and timing associated with the development of those Product or Product Candidates.

Research and development activities account for a significant portion of our operating expenses. We expect our research and development expenses to increase significantly in future periods as we continue to implement our business strategy, which includes advancing our manufacturing technologies and our drug candidates into and through clinical development, expanding our research and development efforts, including hiring additional personnel to support our research and development efforts, ultimately seeking regulatory approvals for our drug candidates that successfully complete clinical trials, and finalizing the integration of, and further developing, BayMedica's operations. In addition, drug candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, although we expect our research and development expenses to increase as our drug candidates advance into later stages of clinical development, we do not believe that it is possible at this time to accurately project total program-specific expenses through to commercialization. There are numerous factors associated with the successful commercialization of any of our Product Candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development.

#### *General and Administrative Expenses*

General and administrative expenses consist of personnel-related costs, including salaries, benefits and stock-based compensation expense, for our personnel in executive, finance and accounting, human resources, business operations and other administrative functions, investor relations activities, legal fees related to corporate matters, fees paid for accounting and tax services, consulting fees and facility-related costs.

We expect our general and administrative expenses will increase for the foreseeable future to support our expanded infrastructure, operating as a public company and increased costs of expanding our operations including as a consequence of the BayMedica acquisition. These increases will likely include increased expenses related to accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company.

**InMed Pharmaceuticals Inc.**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**Three and nine months ended March 31, 2022**

*Amortization and Depreciation*

Intangible assets are comprised of intellectual property that we acquired in 2014 and 2015 and trade secrets, product formulation knowledge, patents and trademarks that we acquired in October 2021. The acquired intellectual property, patents and trademark are amortized on a straight-line basis based on their estimated useful lives. Equipment and leasehold improvements are depreciated using the straight-line method based on their estimated useful lives.

*Share-based Payments*

Share-based payments is the stock-based compensation expense related to our granting of stock options to employees and others. The fair value, at the grant date, of equity-settled share awards is charged to our loss over the period for which the benefits of employees and others providing similar services are expected to be received. The vesting components of graded vesting employee awards are measured separately and expensed over the related tranche's vesting period. The amount recognized as an expense is adjusted to reflect the number of share options expected to vest. The fair value of awards is calculated using the Black-Scholes option pricing model, which considers the exercise price, current market price of the underlying shares, expected life of the award, risk-free interest rate, expected volatility and the dividend yield.

*Other Income*

Other income consists primarily of interest income earned on our cash, cash equivalents and short-term investments.

**Results of Operations**

*Comparison of the three months ended March 31, 2022 and 2021*

|  | <b>Three Months Ended<br/>March 31,</b> |             | <b>Change</b> | <b>% Change</b> |
|--|---|-------------|---------------|-----------------|
|  | <b>2022</b>                             | <b>2021</b> |               |                 |
|  | <b>(in thousands)</b>                   |             |               |                 |
| Sales  | \$ 310                                  | \$ -        | \$ 310        | nm              |
| Cost of sales                                    | 127                                     | -           | 127           | nm              |
| Gross profit                                     | 183                                     | -           | 183           | nm              |
| Operating expenses:                              |   |             |               |                 |
| Research and development and patents             | 1,754                                   | 1,773       | (19)          | -1%             |
| General and administrative                       | 1,915                                   | 1,334       | 581           | 44%             |
| Amortization and depreciation                    | 54                                      | 27          | 27            | 100%            |
| Total operating expenses                         | 3,723                                   | 3,134       | 589           | 19%             |
| Interest and other income                        | 31                                      | 4           | 27            | 675%            |
| Finance expense                                  | -                                       | -           | -             | nm              |
| Unrealized gain on derivative warrants liability | -                                       | -           | -             | nm              |
| Foreign exchange gain (loss)                     | 33                                      | 29          | 4             | 14%             |
| Net loss   | \$ (3,476)                              | \$ (3,101)  | \$ (375)      | 12%             |

**InMed Pharmaceuticals Inc.**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**Three and nine months ended March 31, 2022**

---

*Sales, Cost of Sales and Gross Profit*

We realized sales of \$0.3 million in our BayMedica segment for the three months ended March 31, 2022, the result of manufacturing and distribution sales of bulk rare cannabinoids following the acquisition of BayMedica in October 2021; as the three months ended March 31, 2021 pre-dated the acquisition of BayMedica there are no comparable revenues for InMed in the 2021 period. Accordingly, we realized cost of goods sold of \$0.1 million in our BayMedica segment for the three months ended March 31, 2022, with no comparable expenses in 2021, resulting in a gross profit of \$0.2 million for the period.

*Research and Development and Patents Expenses*

Research and development and patents expenses decreased by \$0.4 million in our InMed segment, or 22%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. The decrease in research and development and patents expenses was primarily due to decreased activities related to the INM-755 clinical trials.

Research and development and patents expenses were \$0.4 million in our BayMedica segment for the three months ended March 31, 2022. The increase in research and development and patents expenses was due to the inclusion of BayMedica operating results following the acquisition date. There were no comparable expenses in 2021.

*General and administrative expenses*

General and administrative expenses increased by \$0.2 million in our InMed segment, or 17%, for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. The increase results primarily from a combination of changes including higher accounting and legal fees and investor relation expenses.

General and administrative expenses were \$0.3 million in our BayMedica segment for the three months ended March 31, 2022. The increase was due to the inclusion of BayMedica operating results following the acquisition date. There were no comparable expenses in 2021.

**InMed Pharmaceuticals Inc.**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**Three and nine months ended March 31, 2022**

*Comparison of the nine months ended March 31, 2022 and 2021*

|  | Nine Months Ended<br>March 31, |            | Change     | % Change |
|--|--------------------------------|------------|------------|----------|
|  | 2022                           | 2021       |            |          |
|  | (in thousands)                 |            |            |          |
| Sales  | \$ 575                         | \$ -       | \$ 575     | nm       |
| Cost of sales                                    | 281                            | -          | 281        | nm       |
| Gross profit                                     | 294                            | -          | 294        | nm       |
| <b>Operating expenses:</b>                       |                                |            |            |          |
| Research and development and patents             | 5,781                          | 3,622      | 2,159      | 60%      |
| General and administrative                       | 5,125                          | 2,918      | 2,207      | 76%      |
| Amortization and depreciation                    | 132                            | 92         | 40         | 43%      |
| Total operating expenses                         | 11,038                         | 6,632      | 4,406      | 66%      |
| Interest and other income                        | 62                             | 11         | 51         | 464%     |
| Finance expense                                  | -                              | (360)      | 360        | -100%    |
| Unrealized gain on derivative warrants liability | -                              | 243        | (243)      | -100%    |
| Foreign exchange loss                            | (48)                           | (206)      | 158        | -77%     |
| Net loss   | \$ (10,730)                    | \$ (6,944) | \$ (3,786) | 55%      |

*Sales, Cost of Sales and Gross Profit*

We realized sales of \$0.6 million in our BayMedica segment for the nine months ended March 31, 2022, the result of manufacturing and distribution sales of bulk rare cannabinoids following the acquisition of BayMedica in October 2021. As the nine months ended March 31, 2021 pre-dated the acquisition of BayMedica there are no comparable revenues in the 2021 period. Accordingly, we realized cost of goods sold of \$0.3 million in our BayMedica segment for the nine months ended March 31, 2022, with no comparable expenses in 2021, resulting in a gross profit of \$0.3 million for the period.

*Research and Development and Patents Expenses*

Research and development and patents expenses increased by \$1.2 million in our InMed segment, or 34%, for the nine months ended March 31, 2022 compared to the nine months ended March 31, 2021. The increase in research and development and patents expenses was primarily due to increased activities related to the INM-755 clinical trials.

Research and development and patents expenses were \$0.9 million in our BayMedica segment for the nine months ended March 31, 2022. The increase in research and development and patents expenses was due to the inclusion of BayMedica operating results following the acquisition date. There were no comparable expenses in 2021.

*General and administrative expenses*

General and administrative expenses increased by \$1.6 million in our InMed segment, or 54%, for the nine months ended March 31, 2022 compared to the nine months ended March 31, 2021. The increase results primarily from a combination of changes including legal fees and investor relation expenses, personnel expenses, substantially higher insurance fees resulting from our listing on the Nasdaq Capital Market. In addition, acquisition-related expenses, which were comprised of regulatory, financial advisory and legal fees, totaled \$0.2 million for the nine months ended March 31, 2022 and were included in general and administrative expenses in our InMed segment.

**InMed Pharmaceuticals Inc.**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**Three and nine months ended March 31, 2022**

---

General and administrative expenses were \$0.6 million in our BayMedica segment for the nine months ended March 31, 2022. The increase is due to the inclusion of BayMedica operating results following the acquisition date. There were no comparable expenses in 2021.

*Finance expense*

Finance expense is \$Nil in our InMed segment for the nine months ended March 31, 2022, compared to \$0.4 million for the nine months ended March 31, 2021. Finance expense is comprised of financing transaction costs, from the November 2020 public offering, allocated to the derivative warrants liability.

*Unrealized gain of derivative warrants liability*

Unrealized gain of derivative warrants liability is \$Nil in our InMed segment for the nine months ended March 31, 2022, compared to \$0.2 million for the nine months ended March 31, 2021, which is the change in fair value of derivative warrants liability during the end of the period.

*Foreign exchange loss*

Foreign exchange loss decreased by \$0.2 million in our InMed segment, or 77%, for the nine months ended March 31, 2022, compared to the nine months ended March 31, 2021, as a consequence of holding non-US denominated assets and liabilities combined with fluctuations in foreign exchange rates.

**Liquidity and Capital Resources**

Since our inception, we have only generated limited revenue from Product sales, no sales from any other sources and have incurred significant operating losses and negative cash flows from our operations. We have only commenced commercial sales with the acquisition of BayMedica and not yet commercialized any of our Product Candidates and we do not expect to generate revenue from sales of any Product Candidates for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of common shares.

As of March 31, 2022, we had cash and cash equivalents of \$5.9 million.

The following table summarizes our cash flows for each of the periods presented:

| <b>(in thousands)</b>                                    | <b>Nine Months<br/>Ended<br/>March 31,<br/>2022</b> | <b>Nine Months<br/>Ended<br/>March 31,<br/>2021</b> |
|--|---|---|
| Net cash used in operating activities                    | \$ (11,537)   | \$ (7,785)  |
| Net cash provided by investing activities                | 53  | -   |
| Net cash provided by financing activities                | 10,019  | 10,938  |
| Effects of foreign exchange on cash and cash equivalents | -   | 495   |
| Net increase (decrease) in cash and cash equivalents     | <u>\$ (1,465)</u>                                   | <u>\$ 3,648</u>                                     |

*Operating Activities*

During the nine months ended March 31, 2022, we used cash in operating activities of \$11.5 million, primarily resulting from our net loss of \$10.7 million offset primarily by changes in our non-cash working capital and non-cash share-based compensation expenses.

During the nine months ended March 31, 2021, we used cash in operating activities of \$7.8 million, primarily resulting from our net loss of \$6.9 million combined with \$1.5 million used in changes in our non-cash working capital, partially offset primarily by non-cash share-based compensation expenses, financing expenses allocated to warrants and changes in the valuation of the derivative warrants liability.

**InMed Pharmaceuticals Inc.**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**Three and nine months ended March 31, 2022**

---

*Investing Activities*

During the nine months ended March 31, 2022, cash provided by investing activities of less than \$0.1 million resulted from cash acquired from the acquisition of BayMedica, partially offset by purchases of property and equipment.

During the nine months ended March 31, 2021, we had no cash provided by or used in investing activities.

*Financing Activities*

During the nine months ended March 31, 2022, cash provided by financing activities of \$10.0 million consisted of \$12.0 million of gross proceeds from a private placement of our common shares, offset by transaction costs of \$1.3 million and settlement of debt of \$0.4 million, reflecting the value of loans to BayMedica as at the date of acquisition, and \$0.3 million for the repayment of debt assumed in the BayMedica acquisition.

During the nine months ended March 31, 2021, cash provided by financing activities of \$10.9 million consisted of \$12.5 million of gross proceeds from a public offering of our common shares offset by transaction costs of \$1.5 million.

**Funding Requirements**

We expect our expenses to increase substantially in connection with our ongoing research and development activities, particularly as we continue the research and development of and the clinical trials for our Product Candidates. In addition, we expect to incur additional costs associated with operating as a US-listed public company and associated with integrating and developing BayMedica's operations. As a result, we expect to incur substantial operating losses and negative operating cash flows for the foreseeable future.

In accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Update ("ASU") 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated interim financial statements are issued.

Through March 31, 2022, we have funded our operations primarily with proceeds from the sale of common stock. We have incurred recurring losses and negative cash flows from operations since its inception, including net losses of \$10.7 million and \$6.9 million for the nine months ended March 31, 2022 and 2021, respectively. In addition, we have an accumulated deficit of \$85.6 million as of March 31, 2022. Our accumulated deficit increased between 2014, when we began focusing on the development of cannabinoid-derived pharmaceuticals following the acquisition of Biogen Science Inc., and March 31, 2022 by approximately \$56.7 million and we expect to continue to generate operating losses for the foreseeable future.

On July 2, 2021, we closed a \$12.0 million private placement. Under the terms of the private placement, an aggregate of 890,000 common shares and 3,146,327 pre-funded warrants, and warrants to purchase up to an aggregate of 4,036,327 common shares, were purchased. The warrants have an exercise price of \$2.848 per share, are exercisable immediately and have a term of five years. After deducting the placement agent fees and estimated offering expenses payable by us, we received net proceeds of approximately \$11.0 million.

In April 2022, we filed a prospectus supplement to our S-3 universal shelf filing to incorporate an At The Market Offering Agreement.

As of the issuance date of this Form 10-Q, we expect our cash and cash equivalents of \$5.9 million as of March 31, 2022 will be sufficient to fund our operating expenses and capital expenditure requirements into the second quarter of fiscal 2023 (being the fourth calendar quarter of 2022). Our future viability beyond that point is dependent on our ability to raise additional capital to finance our operations. In addition, there are a number of uncertainties in estimating our operating expenses and capital expenditure requirements including the impact of potential acquisitions. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated interim financial statements are issued.

We expect to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. We may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our existing stockholders.

Our funding requirements and timing and amount of our operating expenditures will depend largely on:

- the progress, costs and results of our Phase 2 clinical trial;
- the scope, progress, results and costs of discovery research, preclinical development, laboratory testing and clinical trials for our Product Candidates;
- the scope, progress, results and costs of development of our manufacturing technologies;
- the number of and development requirements for other Products and Product Candidates that we pursue;
- the costs, timing and outcome of regulatory review of our Product Candidates;
- our ability to enter into contract manufacturing arrangements for supply of materials and manufacture of our Products and Product Candidates and the terms of such arrangements;
- the impact of any acquired, or in-licensed, externally developed product(s) and/or technologies including those of BayMedica;
- our ability to establish and maintain strategic collaborations, licensing or other arrangements, including sales arrangements, and the financial terms of such arrangements;
- the sales, costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our Products and for Product Candidates for which we may receive marketing approval;
- the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property- related claims;
- expansion costs of our operational, financial and management systems and increases to our personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a dual listed company; and
- the costs to obtain, maintain, expand and protect our intellectual property portfolio.



A change in the outcome of any of these, or other variables with respect to the development of any of our Products and Product Candidates, could significantly change the costs and timing associated with their development. We will need to continue to rely on additional financing to achieve our business objectives.

In addition to the variables described above, if and when any of our Product Candidates successfully complete development, we will incur substantial additional costs associated with regulatory filings, marketing approval, post-marketing requirements, maintaining our intellectual property rights, and regulatory protection, in addition to other commercial costs. We cannot reasonably estimate these costs at this time.

Until such time, if ever, as we can generate substantial revenues from either our Products or Product Candidates, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements. We currently have no credit facility or committed sources of capital. To the extent that we raise additional capital through the future sale of equity securities, the ownership interests of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common shareholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. We may require additional capital beyond our currently anticipated amounts, and additional capital may not be available on reasonable terms, or at all. If we raise additional funds through collaboration arrangements or other strategic transactions in the future, we may have to relinquish valuable rights to our technologies, future revenue streams, Products or Product Candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate development or future commercialization efforts or grant rights to develop and market Products or Product Candidates that we would otherwise prefer to develop and market ourselves.

#### **Off-Balance Sheet Arrangements**

During the periods presented we did not have, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

#### **Critical Accounting Policies and Significant Judgments and Estimates**

We periodically review our financial reporting and disclosure practices and accounting policies to ensure that they provide accurate and transparent information relative to the current economic and business environment. As part of this process, we have reviewed our selection, application and communication of critical accounting policies and financial disclosures. Management has discussed the development and selection of the critical accounting policies with the Audit Committee of the Board of Directors and the Audit Committee has reviewed the disclosure relating to critical accounting policies in this Management's Discussion and Analysis.

This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated interim financial statements included as part of this report, which have been prepared in accordance with U.S. GAAP. The preparation of our condensed consolidated interim financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the revenue and expenses incurred during the reported periods. We base estimates on our historical experience, known trends and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Detailed information about our critical accounting policies and estimates is set forth in Part II, Item 7 of our Annual Report on Form 10-K for the year ended June 30, 2021. In addition, Note 2 to our unaudited condensed consolidated interim financial statements as of and for the three and nine months ended March 31, 2022 include new accounting policies for business combinations, accounts receivable, inventories, revenue recognition, cost of sales and shipping and handling. These policies are considered by management to be essential to understanding the processes and reasoning that go into the preparation of our financial statements and the uncertainties that could have a bearing on its financial results.

### **Business Combination**

Business combinations are accounted for using the acquisition method. The fair value of total purchase consideration is allocated to the fair values of identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount being classified as goodwill. All assets and liabilities acquired or assumed in a business combination are recorded at their fair values at the date of acquisition. If the Company's interest in the fair value of the acquiree's net identifiable assets exceeds the cost of the acquisition, the excess is recognized in earnings or loss immediately. Transaction costs that are incurred in connection with a business combination, other than costs associated with the issuance of debt or equity securities, are expensed as incurred.

As part of our acquisition of BayMedica Inc, on October 13, 2021, goodwill, trade secrets, product formulation knowledge, patents, trademarks, Technology and In-Process Research and Development Intangible ("IPR&D") intangible assets were recognized. The fair value of the aggregate intangible assets was determined to be \$2.7 million and goodwill was \$2.0 million at the acquisition date. IPR&D is classified as indefinite-lived and is not amortized. The multi-period excess earnings method was used to determine the fair value of these assets as at the date of acquisition. All research and development costs incurred subsequent to the acquisition of IPR&D are expensed as incurred. Patents and trademarks are expected to have a finite life and are being amortized on a straight-line basis over their estimated useful lives. Amortization begins when intangible assets with finite lives are put into use.

### **Going Concern**

Through March 31, 2022, we have funded our operations primarily with proceeds from the sale of common shares. We have incurred recurring losses and negative cash flows from operations since our inception, including net losses of \$10.7 million and \$6.9 million for the nine months ended March 31, 2022 and 2021, respectively. In addition, we have an accumulated deficit of \$85.6 million as of March 31, 2022. Our accumulated deficit increased between 2014, when we began focusing on the development of cannabinoid-derived pharmaceuticals following the acquisition of Biogen Science Inc., and March 31, 2022 by approximately \$56.7 million and we expect to continue to generate operating losses for the foreseeable future.

On July 2, 2021, we closed a \$12.0 million private placement and received net proceeds of approximately \$11.0 million.

In April 2022, we filed a prospectus supplement to our S-3 universal shelf filing to incorporate an At The Market Offering Agreement.

As of the issuance date of the condensed consolidated interim financial statements, we expect our cash and cash equivalents of \$5.9 million as of March 31, 2022, will be sufficient to fund our operating expenses and capital expenditure requirements into the second quarter of fiscal 2023 (being the fourth calendar quarter of 2022). Our future viability beyond that point is dependent on our ability to raise additional capital to finance our operations. In addition, there are a number of uncertainties in estimating our operating expenses and capital expenditure requirements including the impact of potential acquisitions. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated interim financial statements are issued.

We expect to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. We may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our existing shareholders.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.**

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and, as such, are not required to provide the information under this Item.

### **ITEM 4. CONTROLS AND PROCEDURES.**

#### **Evaluation of Disclosure Controls and Procedures**

Our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and to ensure that information required to be disclosed is accumulated and communicated to management, including our principal executive and financial officers, to allow timely decisions regarding disclosure. As of March 31, 2022, the Chief Executive Officer and the Interim Chief Financial Officer, with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based upon the evaluation, they have concluded that, as of March 31, 2022, our disclosure controls and procedures were not effective at a reasonable assurance level due to a material weakness that existed in our internal controls over financial reporting resulting from a lack of resources in our finance function, as disclosed in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021.

It should be noted that any system of controls is based in part upon certain assumptions designed to obtain reasonable (and not absolute) assurance as to its effectiveness, and there can be no assurance that any design will succeed in achieving its stated goals.

#### **Changes in Internal Control Over Financial Reporting**

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our fiscal quarter ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

#### **Remediation**

We began implementing a remediation plan to address the previously reported material weakness in internal control over financial reporting, described in Part II, Item 9A, "Controls and Procedures" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021. Remediation measures include adding additional resources in our finance function, changing certain closing reporting processes and utilizing external resources to assist with certain financial reporting matters. The material weakness will not be considered remediated, until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. We expect that the remediation of this material weakness will be completed prior to the end of fiscal year 2022. Notwithstanding the material weakness, we believe the financial statements in this report fairly present, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformity with U.S. GAAP.

## PART II

### ITEM 1. LEGAL PROCEEDINGS.

We are not involved in any material active legal actions. However, from time to time, we may be subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of our business.

### ITEM 1A. RISK FACTORS.

As a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this item. For a discussion of our potential risks and uncertainties, please review the risks and uncertainties described in “Risk Factors” in our Form 10-K dated September 24, 2021 and in our Registration Statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on March 5, 2022.

### ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

### ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

### ITEM 4. MINE SAFETY DISCLOSURE.

None

### ITEM 5. OTHER INFORMATION.

None.

**ITEM 6. EXHIBITS.***Exhibits*

The following exhibits are filed as part of this report:

| <b>Exhibit Number</b> | <b>Description</b>  |
|-----------------------|---|
| 31.1                  | <a href="#">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended</a>                                 |
| 31.2                  | <a href="#">Certification of Interim Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended</a>                         |
| 32.1                  | <a href="#">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a>         |
| 32.2                  | <a href="#">Certification of Interim Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a> |
| 101.INS               | Inline XBRL Instance Document   |
| 101.SCH               | Inline XBRL Taxonomy Extension – Schema   |
| 101.CAL               | Inline XBRL Taxonomy Extension – Calculations   |
| 101.DEF               | Inline XBRL Taxonomy Extension – Definitions  |
| 101.LAB               | Inline XBRL Taxonomy Extension – Labels   |
| 101.PRE               | Inline XBRL Taxonomy Extension – Presentations  |
| 104                   | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)  |

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the *Securities Exchange Act of 1934*, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**INMED PHARMACEUTICALS INC.**  
(Registrant)

Dated: May 13, 2022

By: /s/ Brenda Edwards  
Interim Chief Financial Officer and  
Chief Accounting Officer

## Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Eric A. Adams, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of InMed Pharmaceuticals Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 13, 2022

/s/ Eric A. Adams

Name: Eric A. Adams

Title: President and Chief Executive Officer

## Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Brenda Edwards, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of InMed Pharmaceuticals Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 13, 2022

/s/ Brenda Edwards

Name: Brenda Edwards

Title: Interim Chief Financial Officer



**Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Eric A. Adams, the President and Chief Executive Officer of InMed Pharmaceuticals Inc. (the "Company"), hereby certify that, to my knowledge:

1. The Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the "Report") of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 13, 2022

/s/ Eric A. Adams

Name: Eric A. Adams

Title: President and Chief Executive Officer

**Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Brenda Edwards, the Interim Chief Financial Officer of InMed Pharmaceuticals Inc. (the "Company"), hereby certify that, to my knowledge:

1. The Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the "Report") of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 13, 2022

/s/ Brenda Edwards

Name: Brenda Edwards

Title: Interim Chief Financial Officer